@mushroompanda and @thunderhead I held $M7T (a small position, from which I lost about 8% of my capital,... plus the oppportunity cost) from 2021 until 2024.

My initial thesis was: good SaaS product (award winning), well-tuned to image assessment and diagnosis outside the clinic, competent-if-uninspiring management... a mini-$PME ... as I saw the dust from the $PME bus riding off into the distance, while still wanting to play in the medical imaging space (after all, one of my PhD examiners was a Nobel-Prize winning co-inventor of MRI, so I have a nostalgic connection to the industry!).

Sadly, it never gained critical mass - the operating economics (which I've published here multiple times) never emerged. It just didn't scale. There was a better offer in the market.

I recognised in Jan-24 that equipment-agnostic medical imaging software is looking like a winner-takes-all (or at least the most) play.

Trinity looks like another nail perhaps, although I've now stopped even following $M7T, as I can't even make the case to invest my research time.

Fascinating stuff.

I have held the also-rans too, in a similar vein @mikebrisy. I sold out of IME a long time back, but kept a residual position in M7T which is well underwater, so 8% doesn't sound too bad at all :)